PCN48 Cost-Benefit Analysis of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer
Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.140
https://www.valueinhealthjournal.com/article/S1098-3015(21)00357-0/fulltext
Section Title :
Section Order :
10716
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00357-0&doi=10.1016/j.jval.2021.04.140